Mikhail Blagosklonny is one of the foremost researchers and scientists in oncology. Blagosklonny went to First Pavlov State Medical University of St. Petersburg. He earned a Master’s in Internal Medicine and a Doctorate in Cardiology and Medicine from the University. Mikhail moved to the United States and started his career at the New York Medical College as an associate professor of medicine. His work here led to him being offered a position at the Ordway Research Institute on ImpactJournals.com as a senior scientist. He accepted the job and worked at the Institute which is also located in New York for seven years.
Mikhail accepted a position at the Roswell Park Cancer Institute as an oncology professor in 2009. He is a professor at the Institute to date. Blagosklonny’s career has revolved around cancer, anti-cancer, and anti-aging treatments. He has been focusing on the relation between aging and the diseases that are associated with aging. Mikhail Blagosklonny has written close to 300 papers which have gotten more than 20,000 citations.
One of his articles talks about the role of TOR signaling in cancer and aging. The key to anti-aging would be to reduce the rate at which this development occurs. Cancer is one of the diseases that arise from development. There are specific cancer treatments on tandfonline.com that delay this development. Rapamycin is one of these drugs. Studies have shown that it increases the life span of people that take it.
Mikhail’s research in Oncology led him to start Oncotarget where he is one of the editors-in-chief. Oncotarget is a peer review medical journal on oncology. It is released weekly. It has grown to become one of the top journals in the world since it was started six years ago. The journal has an impact factor of 5.0. This is a testament to the level of quality of the papers that are published in the journal. Oncotarget is released online and is easily accessible. He is currently the editor-in-chief of two other journals known as Aging and Cell Cycle.